RSS
ALNY icon

Rosenblum Silverman Sutton’s Alnylam Pharmaceuticals ALNY Stock Holding History

Rosenblum Silverman Sutton’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.9M Sell
32,927
-253
-0.8% -$86.1K 2.85% 12
2025
Q4 		$13.2M Sell
33,180
-822
-2% -$364K 3.05% 11
2025
Q3 		$15.5M Sell
34,002
-390
-1% -$159K 3.54% 8
2025
Q2 		$11.2M Sell
34,392
-240
-0.7% -$66.4K 2.72% 11
2025
Q1 		$9.35M Sell
34,632
-143
-0.4% -$36.8K 2.58% 13
2024
Q4 		$8.18M Sell
34,775
-380
-1% -$99.9K 2.06% 16
2024
Q3 		$9.67M Sell
35,155
-45
-0.1% -$11.7K 2.47% 15
2024
Q2 		$8.55M Sell
35,200
-270
-0.8% -$42.6K 2.29% 15
2024
Q1 		$5.3M Sell
35,470
-467
-1% -$77.9K 1.5% 23
2023
Q4 		$6.88M Sell
35,937
-1,116
-3% -$190K 2.19% 16
2023
Q3 		$6.56M Sell
37,053
-100
-0.3% -$19.1K 2.23% 15
2023
Q2 		$7.06M Sell
37,153
-390
-1% -$77.3K 2.33% 15
2023
Q1 		$7.52M Sell
37,543
-2,340
-6% -$492K 2.74% 13
2022
Q4 		$9.48M Sell
39,883
-246
-0.6% -$52.5K 3.45% 10
2022
Q3 		$8.03M Sell
40,129
-2,477
-6% -$472K 2.9% 10
2022
Q2 		$6.21M Buy
42,606
+845
+2% +$120K 2.02% 17
2022
Q1 		$6.82M Sell
41,761
-598
-1% -$91.1K 1.75% 22
2021
Q4 		$7.18M Sell
42,359
-665
-2% -$124K 1.62% 25
2021
Q3 		$8.12M Sell
43,024
-417
-1% -$78.2K 1.86% 21
2021
Q2 		$7.36M Buy
43,441
+546
+1% +$80K 1.66% 22
2021
Q1 		$6.06M Buy
42,895
+805
+2% +$121K 1.55% 26
2020
Q4 		$5.47M Buy
42,090
+235
+0.6% +$31.4K 1.43% 27
2020
Q3 		$6.09M Buy
41,855
+2,860
+7% +$406K 1.71% 23
2020
Q2 		$5.78M Buy
38,995
+1,325
+4% +$179K 1.85% 23
2020
Q1 		$4.1M Buy
+37,670
New +$4.35M 1.64% 23

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rosenblum Silverman Sutton's ALNY Position: Q1 2026 in Review

Rosenblum Silverman Sutton reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.76% in Q1 2026, selling an estimated $86.1K and leaving 32,927 shares worth $10.9M. The position accounts for 2.85% of the portfolio, ranked #12.

Rosenblum Silverman Sutton first reported a position in ALNY in Q1 2020 and has held it in 25 quarters since. The position peaked at $15.5M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Rosenblum Silverman Sutton held 32,927 shares of Alnylam Pharmaceuticals worth $10.9M as of Q1 2026.
  • Rosenblum Silverman Sutton sold 253 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $86.1K.
  • Alnylam Pharmaceuticals made up 2.85% of Rosenblum Silverman Sutton's portfolio in Q1 2026, its #12 holding.
  • Rosenblum Silverman Sutton first reported a position in Alnylam Pharmaceuticals in Q1 2020 and has held it in 25 quarters since.
  • Rosenblum Silverman Sutton's Alnylam Pharmaceuticals position peaked at $15.5M in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Rosenblum Silverman Sutton's 13F filing for Q1 2026, filed 13 May 2026.